A pilot study of recombinant human TNF and interferon-gamma in four patients with refractory AML

Eur J Haematol. 1992 Feb;48(2):115-6. doi: 10.1111/j.1600-0609.1992.tb00576.x.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Female
  • Humans
  • Interferon-gamma / administration & dosage
  • Interferon-gamma / adverse effects
  • Interferon-gamma / therapeutic use*
  • Leukemia, Myeloid, Acute / blood
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • Pilot Projects
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Tumor Necrosis Factor-alpha / administration & dosage
  • Tumor Necrosis Factor-alpha / adverse effects
  • Tumor Necrosis Factor-alpha / therapeutic use*

Substances

  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Interferon-gamma